JP2007532510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532510A5 JP2007532510A5 JP2007506734A JP2007506734A JP2007532510A5 JP 2007532510 A5 JP2007532510 A5 JP 2007532510A5 JP 2007506734 A JP2007506734 A JP 2007506734A JP 2007506734 A JP2007506734 A JP 2007506734A JP 2007532510 A5 JP2007532510 A5 JP 2007532510A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- composition
- oligopeptide
- serum
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 102000015636 Oligopeptides Human genes 0.000 claims 16
- 108010038807 Oligopeptides Proteins 0.000 claims 16
- 238000000034 method Methods 0.000 claims 14
- 210000002966 serum Anatomy 0.000 claims 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- DXRXYJYFADHAPA-AUTRQRHGSA-N (2s)-2-[[2-[[(2s)-5-amino-2-[[(2s)-2-aminopropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N DXRXYJYFADHAPA-AUTRQRHGSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 206010063897 Renal ischaemia Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/821,256 US20050227925A1 (en) | 2004-04-08 | 2004-04-08 | Compositions capable of reducing elevated blood urea concentration |
| US10/821,256 | 2004-04-08 | ||
| PCT/EP2005/003707 WO2005097163A1 (en) | 2004-04-08 | 2005-04-08 | Oligopeptides for reducing elevated blood urea concentration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007532510A JP2007532510A (ja) | 2007-11-15 |
| JP2007532510A5 true JP2007532510A5 (enExample) | 2008-09-04 |
| JP4732438B2 JP4732438B2 (ja) | 2011-07-27 |
Family
ID=34963497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506734A Expired - Fee Related JP4732438B2 (ja) | 2004-04-08 | 2005-04-08 | 上昇した血中尿素濃度を低減させるオリゴペプチド |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20050227925A1 (enExample) |
| EP (1) | EP1755634B1 (enExample) |
| JP (1) | JP4732438B2 (enExample) |
| KR (1) | KR101217025B1 (enExample) |
| CN (1) | CN101014356B (enExample) |
| AT (1) | ATE410178T1 (enExample) |
| AU (1) | AU2005230403B2 (enExample) |
| CA (1) | CA2561833C (enExample) |
| CY (1) | CY1108689T1 (enExample) |
| DE (1) | DE602005010246D1 (enExample) |
| DK (1) | DK1755634T3 (enExample) |
| ES (1) | ES2315858T3 (enExample) |
| HR (1) | HRP20090003T3 (enExample) |
| IL (1) | IL178515A (enExample) |
| NZ (1) | NZ550574A (enExample) |
| PL (1) | PL1755634T3 (enExample) |
| PT (1) | PT1755634E (enExample) |
| RS (1) | RS50727B (enExample) |
| SI (1) | SI1755634T1 (enExample) |
| WO (1) | WO2005097163A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
| US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
| US6844315B2 (en) | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
| US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
| US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
| US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
| US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
| US7501391B2 (en) * | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
| US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
| US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
| US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
| US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
| US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
| US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
| US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
| AU2006266609C1 (en) * | 2005-07-05 | 2011-10-27 | Biotempt B.V. | Treatment of tumors |
| DE102005045152A1 (de) * | 2005-09-21 | 2007-03-22 | Stremmel, Wolfgang, Prof. Dr. | Verwendung von therapeutisch wirksamen Lipiden nebst Verfahren zur Herstellung von Organ-/Gewebe-spezifischen therapeutisch wirksamen Lipiden |
| EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| CN101443080B (zh) * | 2006-03-07 | 2015-01-14 | 比奥滕普特公司 | 肽在控制辐射损伤中的用途 |
| NZ578956A (en) * | 2007-02-12 | 2012-02-24 | Biotempt Bv | Treatment of trauma hemorrhage with short oligopeptides |
| WO2009014440A1 (en) * | 2007-07-23 | 2009-01-29 | Biotempt B.V. | Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides |
| CN113499349B (zh) * | 2021-07-13 | 2023-11-21 | 西南民族大学 | 一种慢性肾功能衰竭治疗用爬沙虫提取物及其制备方法和应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5822474B2 (ja) * | 1980-06-10 | 1983-05-09 | 天野製薬株式会社 | コレシストキニン・パンクレオザイミンｃ端ペプチドアミドスルフエ−トエステルの製造法 |
| US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
| US4571336A (en) * | 1983-08-25 | 1986-02-18 | Endorphin, Inc. | Immune stimulation |
| US4977244A (en) * | 1985-06-27 | 1990-12-11 | The United States Of America As Represented By The Department Of Health And Human Services | Uromodulin and a process of purifying it |
| US4855285A (en) * | 1985-12-04 | 1989-08-08 | The Ohio State University Research Foundation | Antigenic modification of polypeptides |
| US4753965A (en) * | 1987-04-09 | 1988-06-28 | Merrell Dow Pharmaceuticals, Inc. | Method of treating multiple sclerosis with chalcone derivatives |
| US5002961A (en) * | 1987-10-19 | 1991-03-26 | Merrell Dow Pharmaceuticals | Method for reducing injury with imidazol-2-thionecarboxamides |
| DE68926178T2 (de) * | 1988-05-10 | 1996-11-28 | Alpha 1 Biomedicals Inc | Festphase-Verfahren zur Gewinnung von Thymosin-alpha-1 |
| US5055447A (en) * | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
| US6051596A (en) * | 1990-08-10 | 2000-04-18 | Anormed, Inc. | Immunosuppressive compositions |
| US5958413A (en) * | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
| US5223397A (en) * | 1991-06-05 | 1993-06-29 | Sangstat Medical Corporation | Soluble hla cross-match |
| DE4138621A1 (de) * | 1991-11-25 | 1993-06-17 | Boehringer Ingelheim Int | Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg |
| PT633929E (pt) * | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
| US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
| US5380668A (en) * | 1993-07-06 | 1995-01-10 | University Of Utah Research Foundation | Compounds having the antigenicity of hCG |
| NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| US5677275A (en) * | 1994-08-05 | 1997-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
| US5851997A (en) * | 1994-10-04 | 1998-12-22 | Harris; Pamela Jo | Use of human chorionic gonadotropin as an immune-potentiating antiviral agent |
| SE520730C2 (sv) * | 1995-01-20 | 2003-08-19 | Eskil Elmer | Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel |
| EP0867448A4 (en) * | 1995-04-13 | 2000-04-26 | Chugai Pharmaceutical Co Ltd | PEPTID which suppresses the 1xBalpha PHOSPHORY READING |
| US5942494A (en) * | 1995-10-06 | 1999-08-24 | The Trustees Of Columbia University In The City Of New York | Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70) |
| US6361992B1 (en) * | 1996-05-08 | 2002-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Thyroid stimulating hormone superagonists |
| US5968513A (en) * | 1996-06-24 | 1999-10-19 | University Of Maryland Biotechnology Institute | Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
| US5997871A (en) * | 1996-06-24 | 1999-12-07 | University Of Maryland Biotechnology Insitute | Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin |
| US6319504B1 (en) * | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
| US6150500A (en) * | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
| GB9624927D0 (en) * | 1996-11-29 | 1997-01-15 | Oxford Glycosciences Uk Ltd | Gels and their use |
| US5966712A (en) * | 1996-12-12 | 1999-10-12 | Incyte Pharmaceuticals, Inc. | Database and system for storing, comparing and displaying genomic information |
| US6416959B1 (en) * | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
| US5801193A (en) * | 1997-04-15 | 1998-09-01 | Immune Modulation, Inc. | Compositions and methods for immunosuppressing |
| US6583109B1 (en) * | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| US6831057B2 (en) * | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
| US6075150A (en) * | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
| US7175679B2 (en) * | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
| US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
| EP1138692A1 (en) * | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US6921751B1 (en) * | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
| JP2002531384A (ja) * | 1998-11-20 | 2002-09-24 | マウント サイナイ ホスピタル | ＢクラスｅｐｈｒｉｎとＰＤＺ領域との相互作用を変調するペプチド |
| US6507788B1 (en) * | 1999-02-25 | 2003-01-14 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function |
| US6310041B1 (en) * | 1999-03-09 | 2001-10-30 | Fornix Biosciences N.V. | Synthetic complementary peptides and ophthalmologic uses thereof |
| US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US6379970B1 (en) * | 1999-04-30 | 2002-04-30 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Analysis of differential protein expression |
| RU2157233C1 (ru) * | 1999-05-11 | 2000-10-10 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения |
| US6630138B2 (en) * | 2000-02-11 | 2003-10-07 | Eli Lilly And Company | Protein C derivatives |
| WO2001068113A1 (en) * | 2000-03-10 | 2001-09-20 | Monsanto Technology Llc | Anti-hypertensive peptides |
| US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
| US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| US6783757B2 (en) * | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
| US6539102B1 (en) * | 2000-09-01 | 2003-03-25 | Large Scale Proteomics | Reference database |
| EP1217540A1 (en) * | 2000-11-29 | 2002-06-26 | Lafayette Software Inc. | Methods of organizing data and processing queries in a database system, and database system and software product for implementing such method |
| US7368535B2 (en) * | 2001-05-24 | 2008-05-06 | Trillium Therapeutics Inc. | CD200 receptors |
| US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
| US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
| US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
| US7501391B2 (en) * | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
| US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
| US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
| US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
| US7135286B2 (en) * | 2002-03-26 | 2006-11-14 | Perlegen Sciences, Inc. | Pharmaceutical and diagnostic business systems and methods |
| US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
-
2004
- 2004-04-08 US US10/821,256 patent/US20050227925A1/en not_active Abandoned
-
2005
- 2005-04-08 WO PCT/EP2005/003707 patent/WO2005097163A1/en not_active Ceased
- 2005-04-08 AT AT05729655T patent/ATE410178T1/de active
- 2005-04-08 CA CA2561833A patent/CA2561833C/en not_active Expired - Lifetime
- 2005-04-08 SI SI200530534T patent/SI1755634T1/sl unknown
- 2005-04-08 PT PT05729655T patent/PT1755634E/pt unknown
- 2005-04-08 DK DK05729655T patent/DK1755634T3/da active
- 2005-04-08 AU AU2005230403A patent/AU2005230403B2/en not_active Ceased
- 2005-04-08 CN CN2005800120799A patent/CN101014356B/zh not_active Expired - Fee Related
- 2005-04-08 JP JP2007506734A patent/JP4732438B2/ja not_active Expired - Fee Related
- 2005-04-08 NZ NZ550574A patent/NZ550574A/en not_active IP Right Cessation
- 2005-04-08 EP EP05729655A patent/EP1755634B1/en not_active Expired - Lifetime
- 2005-04-08 DE DE602005010246T patent/DE602005010246D1/de not_active Expired - Lifetime
- 2005-04-08 HR HR20090003T patent/HRP20090003T3/xx unknown
- 2005-04-08 PL PL05729655T patent/PL1755634T3/pl unknown
- 2005-04-08 RS RSP-2009/0001A patent/RS50727B/sr unknown
- 2005-04-08 ES ES05729655T patent/ES2315858T3/es not_active Expired - Lifetime
- 2005-10-13 US US11/249,541 patent/US20060142205A1/en not_active Abandoned
-
2006
- 2006-10-04 KR KR1020067020781A patent/KR101217025B1/ko not_active Expired - Fee Related
- 2006-10-05 IL IL178515A patent/IL178515A/en active IP Right Grant
-
2009
- 2009-01-07 CY CY20091100001T patent/CY1108689T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532510A5 (enExample) | ||
| Ferrario et al. | Angiotensin-(1–7): a bioactive fragment of the renin–angiotensin system | |
| Fisher et al. | Renin inhibition: what are the therapeutic opportunities? | |
| McInnes et al. | Drug interactions that matter: a critical reappraisal | |
| Haschke et al. | Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects | |
| JP4723476B2 (ja) | 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療 | |
| CY1108689T1 (el) | Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα | |
| Fisher et al. | Is there a future for renin inhibitors? | |
| JP2002527727A5 (enExample) | ||
| JP2006514607A5 (enExample) | ||
| Carlsson | The renin-angiotensin system in the endocrine pancreas | |
| JP2021505620A5 (enExample) | ||
| JP2006008706A (ja) | 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置 | |
| CN106632272A (zh) | 白蛋白结合型5‑氟尿嘧啶前体药物的合成及应用 | |
| Iso et al. | A new potent inhibitor of converting enzyme:(2R, 4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid (SA446) | |
| IL314821A (en) | Novel therapeutic uses of gardnerella endolysins | |
| CN104031141A (zh) | 用于治疗2型糖尿病的长效肠激素多肽类似物及应用 | |
| JP4850514B2 (ja) | インターフェロンβ複合体 | |
| US8066982B2 (en) | Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing and treating HIV | |
| JPWO1997007820A1 (ja) | 心疾患治療剤 | |
| Muriel et al. | Effect of Alpha-lnterferon on Erythrocyte and Hepatocyte Plasma Membranes Derived from Cirrhotic Rats | |
| US10596232B2 (en) | Methods and compositions related to long half-life coagulation complexes | |
| Pasin et al. | Interventions Increasing Mortality | |
| Colomb et al. | through proteolysis¹: hydrolysis of a single peptide bond in mono | |
| JP2006528663A5 (enExample) |